Prosight Management, LP - Q4 2020 holdings

$216 Million is the total value of Prosight Management, LP's 42 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 74.5% .

 Value Shares↓ Weighting
ALXN BuyALEXION PHARMACEUTICALS INC$27,457,000
+107.2%
175,738
+51.8%
12.69%
+101.3%
ORGO BuyORGANOGENESIS HLDGS INC$15,237,000
+486.5%
2,023,441
+199.1%
7.04%
+469.6%
PRTA BuyPROTHENA CORP PLC$13,105,000
+140.6%
1,091,202
+100.1%
6.06%
+133.7%
CUE BuyCUE BIOPHARMA INC$11,341,000
+6.1%
906,569
+27.7%
5.24%
+3.1%
ARNA SellARENA PHARMACEUTICALS INC$11,194,000
-8.2%
145,700
-10.6%
5.17%
-10.8%
BMY SellBRISTOL-MYERS SQUIBB CO$10,483,000
-6.3%
169,000
-8.9%
4.84%
-8.9%
BAX SellBAXTER INTL INC$9,715,000
-1.0%
121,075
-0.8%
4.49%
-3.8%
EHC BuyENCOMPASS HEALTH CORP$9,451,000
+34.8%
114,300
+5.9%
4.37%
+30.9%
CI SellCIGNA CORP NEW$8,622,000
+8.3%
41,418
-11.9%
3.98%
+5.2%
CHNG SellCHANGE HEALTHCARE INC$7,843,000
-13.4%
420,514
-32.6%
3.62%
-15.9%
AUPH SellAURINIA PHARMACEUTICALS INC$7,036,000
-19.7%
508,715
-14.5%
3.25%
-22.0%
VRTX NewVERTEX PHARMACEUTICALS INC$6,830,00028,900
+100.0%
3.16%
ALBO BuyALBIREO PHARMA INC$6,556,000
+60.4%
174,791
+42.7%
3.03%
+55.8%
BuyALEXION PHARMACEUTICALS INCcall$6,250,000
+60.6%
40,000
+17.6%
2.89%
+56.0%
ALDX SellALDEYRA THERAPEUTICS INC$6,232,000
-23.0%
908,488
-16.8%
2.88%
-25.2%
MGTX SellMEIRAGTX HLDGS PLC$5,770,000
+11.4%
381,119
-2.6%
2.67%
+8.2%
ZBH SellZIMMER BIOMET HOLDINGS INC$5,470,000
-17.3%
35,501
-27.0%
2.53%
-19.7%
CARA BuyCARA THERAPEUTICS INC$4,449,000
+100.2%
294,041
+68.4%
2.06%
+94.5%
MTCR BuyMETACRINE INC$4,428,000
-16.4%
563,303
+8.6%
2.05%
-18.8%
INOV NewINOVALON HLDGS INC$4,195,000230,877
+100.0%
1.94%
SellAPTOSE BIOSCIENCES INC$3,613,000
-47.1%
824,795
-27.6%
1.67%
-48.7%
NewTWIST BIOSCIENCE CORPput$3,532,00025,000
+100.0%
1.63%
MGLN NewMAGELLAN HEALTH INC$3,145,00037,969
+100.0%
1.45%
ZGNX SellZOGENIX INC$2,989,000
-7.8%
149,522
-17.4%
1.38%
-10.4%
CNC SellCENTENE CORP DEL$2,401,000
-65.1%
40,000
-66.1%
1.11%
-66.1%
NewPROTHENA CORP PLCcall$2,104,000175,200
+100.0%
0.97%
QURE SellUNIQURE NV$1,947,000
-69.2%
53,900
-68.6%
0.90%
-70.0%
ADMA BuyADMA BIOLOGICS INC$1,722,000
+34.5%
883,214
+65.0%
0.80%
+30.7%
NewVERACYTE INCput$1,713,00035,000
+100.0%
0.79%
RETA SellREATA PHARMACEUTICALS INCcl a$1,497,000
-86.6%
12,112
-89.4%
0.69%
-87.0%
NewSPDR SER TRput$1,408,00010,000
+100.0%
0.65%
NewARENA PHARMACEUTICALS INCcall$1,383,00018,000
+100.0%
0.64%
IMTX SellIMMATICS N.V$1,133,000
-5.9%
104,999
-7.5%
0.52%
-8.7%
PRQR NewPROQR THRAPEUTICS N V$1,071,000255,000
+100.0%
0.50%
MIRM NewMIRUM PHARMACEUTICALS INC$1,052,00060,250
+100.0%
0.49%
MGTA SellMAGENTA THERAPEUTICS INC$985,000
-40.7%
125,654
-48.6%
0.46%
-42.4%
NewARK ETF TRput$933,00010,000
+100.0%
0.43%
NewBEAM THERAPEUTICS INCput$816,00010,000
+100.0%
0.38%
NewAKUMIN INC$675,000224,273
+100.0%
0.31%
LHCG NewLHC GROUP INC$586,0002,746
+100.0%
0.27%
ACIU SellAC IMMUNE SA$46,000
-99.0%
8,942
-99.0%
0.02%
-99.0%
MRNA NewMODERNA INC$18,000174
+100.0%
0.01%
ExitREATA PHARMACEUTICALS INCcall$0-1,600
-100.0%
-0.07%
BEAT ExitBIOTELEMETRY INC$0-6,000
-100.0%
-0.13%
MITO ExitSTEALTH BIOTHERAPEUTICS CORPsponsored ads$0-256,044
-100.0%
-0.16%
KIDS ExitORTHOPEDIATRICS CORP$0-8,399
-100.0%
-0.18%
APEN ExitAPOLLO ENDOSURGERY INC$0-277,590
-100.0%
-0.22%
EVFM ExitEVOFEM BIOSCIENCES INC$0-250,000
-100.0%
-0.28%
NLTX ExitNEOLEUKIN THERAPEUTICS INC$0-66,376
-100.0%
-0.38%
KRTX ExitKARUNA THERAPEUTICS INC$0-15,826
-100.0%
-0.58%
BTAI ExitBIOXCEL THERAPEUTICS INC$0-29,800
-100.0%
-0.62%
CBIO ExitCATALYST BIOSCIENCES INC$0-301,678
-100.0%
-0.62%
ESTA ExitESTABLISHMENT LABS HLDGS INC$0-86,042
-100.0%
-0.76%
QDEL ExitQUIDEL CORP$0-7,500
-100.0%
-0.78%
KZR ExitKEZAR LIFE SCIENCES INC$0-365,981
-100.0%
-0.84%
ONEM Exit1LIFE HEALTHCARE INC$0-65,778
-100.0%
-0.89%
AMRX ExitAMNEAL PHARMACEUTICALS INC$0-512,659
-100.0%
-0.95%
KURA ExitKURA ONCOLOGY INC$0-107,367
-100.0%
-1.56%
CLLS ExitCELLECTIS S Aspon ads$0-185,180
-100.0%
-1.63%
ExitISHARES TRput$0-24,000
-100.0%
-1.71%
TBIO ExitTRANSLATE BIO INC$0-282,100
-100.0%
-1.83%
IOVA ExitIOVANCE BIOTHERAPEUTICS INC$0-120,606
-100.0%
-1.89%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-02-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ALDEYRA THERAPEUTICS INC19Q2 20236.2%
ALBIREO PHARMA INC18Q4 20229.2%
MEIRAGTX HOLDINGS PLC18Q3 20236.3%
KEZAR LIFE SCIENCES INC17Q3 20238.2%
ARENA PHARMACEUTICALS INC16Q4 20218.2%
IOVANCE BIOTHERAPEUTICS INC16Q1 20227.7%
CENTENE CORP DEL16Q3 20235.3%
CUE BIOPHARMA INC14Q1 20235.6%
PROTHENA CORP PLC13Q3 202313.6%
ZIMMER BIOMET HOLDINGS INC13Q3 20219.8%

View Prosight Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Prosight Management, LP Q4 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
EXICURE, INC.February 14, 20222,426,5082.2%
Aldeyra Therapeutics, Inc.February 12, 2021908,4882.3%
Teligent, Inc.February 14, 20201,484,5272.8%
Cidara Therapeutics, Inc.February 14, 2019245,7640.9%
Eiger BioPharmaceuticals, Inc.Sold outFebruary 14, 201900.0%
Millendo Therapeutics, Inc.February 14, 2019256,7392.0%
OvaScience, Inc.October 26, 20181,991,1005.6%
CHIMERIX INCFebruary 13, 20181,478,5193.1%
Harvard Apparatus Regenerative Technology, Inc.February 12, 2016184,3601.4%

View Prosight Management, LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G2024-01-02
13F-HR2023-11-14
SC 13G2023-09-01

View Prosight Management, LP's complete filings history.

Compare quarters

Export Prosight Management, LP's holdings